Dynamic Technology Lab Private Ltd Acquires Shares of 18,528 AMAG Pharmaceuticals, Inc. (AMAG)

Dynamic Technology Lab Private Ltd acquired a new position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 18,528 shares of the specialty pharmaceutical company’s stock, valued at approximately $342,000. Dynamic Technology Lab Private Ltd owned about 0.05% of AMAG Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Macquarie Group Ltd. bought a new position in shares of AMAG Pharmaceuticals during the third quarter worth about $266,000. 361 Capital LLC bought a new position in shares of AMAG Pharmaceuticals during the third quarter worth about $197,000. Russell Investments Group Ltd. raised its position in shares of AMAG Pharmaceuticals by 14.2% during the third quarter. Russell Investments Group Ltd. now owns 645,182 shares of the specialty pharmaceutical company’s stock worth $11,903,000 after acquiring an additional 80,217 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of AMAG Pharmaceuticals by 58.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock worth $243,000 after acquiring an additional 4,870 shares during the last quarter. Finally, Sei Investments Co. raised its position in shares of AMAG Pharmaceuticals by 46.3% during the third quarter. Sei Investments Co. now owns 15,795 shares of the specialty pharmaceutical company’s stock worth $291,000 after acquiring an additional 4,996 shares during the last quarter.

A number of equities analysts have recently issued reports on the company. BidaskClub downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Cowen restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, August 10th. Cantor Fitzgerald restated a “hold” rating and set a $21.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Finally, Morgan Stanley lowered their price objective on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $24.00.

Shares of AMAG Pharmaceuticals, Inc. (AMAG) opened at $14.00 on Friday. AMAG Pharmaceuticals, Inc. has a one year low of $11.93 and a one year high of $36.83. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.

COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/03/dynamic-technology-lab-private-ltd-acquires-shares-of-18528-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit